



PolyNovo Limited  
ABN 96 083 866 862

2/320 Lorimer Street  
Port Melbourne  
VIC Australia 3207

P +61 (0) 3 8681 4050  
F +61 (0) 3 8681 4099

23 March 2023

## ASX Announcement

### Share Sale

Chairman Mr David Williams has sold 4.75m shares, the proceeds of which will part settle a US property purchase. Mr Williams still holds 21,384,432 fully paid ordinary shares and does not intend to sell more shares for the foreseeable future.

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

#### Further information:

David Williams  
Chairman  
Mobile: + 61 414 383 593

Jan Gielen  
CFO & Company Secretary  
Mobile: + 61 411 787 123

#### About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care. PolyNovo is an Australian based medical device company that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopedic applications. For further information and market presentations see [www.polyново.com](http://www.polyново.com)

#### About NovoSorb®

NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn. NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fibre, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and a programmable bio-resorption profile.

## Appendix 3Y

### Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	PolyNovo Limited
<b>ABN</b>	96 083 866 862

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr David Williams
<b>Date of last notice</b>	22 February 2023

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect.																								
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Lawn Views Pty Ltd is a related entity of Mr Williams in that his spouse is a director and controller of the company.																								
<b>Date of change</b>	17 March 2023 to 22 March 2023																								
<b>No. of securities held prior to change</b>	Across all holdings: 26,134,432 ordinary fully paid shares.																								
<b>Class</b>	Ordinary fully paid shares.																								
<b>Number acquired</b>	NIL																								
<b>Number disposed by Lawn Views Pty Ltd</b>	4,750,000 ordinary fully paid shares.																								
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	<p>\$9,700,829.24 received by Lawn Views Pty Ltd for sale of 4,750,000 ordinary shares via on markets trades:</p> <table><tr><th>Trade Date</th><th># Shares</th><th>Price</th><th>Proceeds</th></tr><tr><td>17-Mar-23</td><td>4,000,000</td><td>\$ 2.0400</td><td>\$ 8,160,000.00</td></tr><tr><td>20-Mar-23</td><td>305,451</td><td>\$ 2.0709</td><td>\$ 632,556.95</td></tr><tr><td>21-Mar-23</td><td>216,896</td><td>\$ 2.0424</td><td>\$ 442,986.44</td></tr><tr><td>22-Mar-23</td><td>227,653</td><td>\$ 2.0438</td><td>\$ 465,285.85</td></tr><tr><td><b>Total</b></td><td><b>4,750,000</b></td><td></td><td><b>\$ 9,700,829.24</b></td></tr></table>	Trade Date	# Shares	Price	Proceeds	17-Mar-23	4,000,000	\$ 2.0400	\$ 8,160,000.00	20-Mar-23	305,451	\$ 2.0709	\$ 632,556.95	21-Mar-23	216,896	\$ 2.0424	\$ 442,986.44	22-Mar-23	227,653	\$ 2.0438	\$ 465,285.85	<b>Total</b>	<b>4,750,000</b>		<b>\$ 9,700,829.24</b>
Trade Date	# Shares	Price	Proceeds																						
17-Mar-23	4,000,000	\$ 2.0400	\$ 8,160,000.00																						
20-Mar-23	305,451	\$ 2.0709	\$ 632,556.95																						
21-Mar-23	216,896	\$ 2.0424	\$ 442,986.44																						
22-Mar-23	227,653	\$ 2.0438	\$ 465,285.85																						
<b>Total</b>	<b>4,750,000</b>		<b>\$ 9,700,829.24</b>																						

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	Across all holdings: 21,384,432 ordinary fully paid shares.
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares sold via on market trades.

#### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

#### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.